Alkermes plc. Proceeds from Divestiture of Businesses
Alkermes plc. (ALKS) reported Proceeds from Divestiture of Businesses of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromDivestitureOfBusinesses · last filed 2026-07-28
- Alkermes plc. proceeds from divestiture of businesses for the quarter ending 2025-12-31 was $0.00.
- Alkermes plc. proceeds from divestiture of businesses for the quarter ending 2025-09-30 was $0.00.
- Alkermes plc. proceeds from divestiture of businesses for the quarter ending 2024-12-31 was $0.00.
- Alkermes plc. proceeds from divestiture of businesses for the quarter ending 2024-09-30 was $0.00.
- Alkermes plc. proceeds from divestiture of businesses for fiscal 2025 was $1.71M, a 98.26% decline from fiscal 2024.
- Alkermes plc. proceeds from divestiture of businesses for fiscal 2024 was $97.93M.
| Period end | Proceeds from Divestiture of Businesses 3 month | Proceeds from Divestiture of Businesses 6 month | Proceeds from Divestiture of Businesses 9 month | Proceeds from Divestiture of Businesses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-07-28 | |||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $1.71M 10-K · filed 2026-02-25 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $1.71M 10-Q · filed 2025-10-28 | ||
| 2025-06-30 | $1.71M 10-Q · filed 2026-07-28 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $97.93M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $97.93M 10-Q · filed 2025-10-28 | ||
| 2024-06-30 | $97.93M 10-Q · filed 2025-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |